Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cytokinetics (CYTK) FCF Margin: 2009-2025

Historic FCF Margin for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to -6,035.85%.

  • Cytokinetics' FCF Margin rose 1603780.00% to -6,035.85% in Q3 2025 from the same period last year, while for Sep 2025 it was -531.67%, marking a year-over-year increase of 1211356.00%. This contributed to the annual value of -2,665.37% for FY2024, which is 285586.00% up from last year.
  • Latest data reveals that Cytokinetics reported FCF Margin of -6,035.85% as of Q3 2025, which was down 2,943.22% from -198.34% recorded in Q2 2025.
  • Cytokinetics' 5-year FCF Margin high stood at -105.17% for Q2 2022, and its period low was -39,949.40% during Q2 2024.
  • In the last 3 years, Cytokinetics' FCF Margin had a median value of -8,694.17% in 2025 and averaged -12,713.06%.
  • Per our database at Business Quant, Cytokinetics' FCF Margin plummeted by 2,582,587bps in 2024 and then spiked by 3,975,106bps in 2025.
  • Cytokinetics' FCF Margin (Quarterly) stood at -113.92% in 2021, then tumbled by 506,723bps to -5,181.14% in 2022, then skyrocketed by 74,849bps to -4,432.66% in 2023, then surged by 398,686bps to -445.80% in 2024, then soared by 1,603,780bps to -6,035.85% in 2025.
  • Its FCF Margin stands at -6,035.85% for Q3 2025, versus -198.34% for Q2 2025 and -8,694.17% for Q1 2025.